Lundquist Logo.png

Interested in trying out a male birth control method?

Participate in a research study.

Help us develop a new
male contraceptive gel.
Contribute to discoveries that may improve health care for you and your family!

Contact Us:

Michael Massone

Study Coordinator

(310) 222-1873

michael.massone@lundquist.org

Elizabeth Ruiz

Study Coordinator

(310) 222-1728

eruiz@lundquist.org

Investigator

Wang.jpg

Christina Wang, MD
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Assistant Dean, Clinical and Translational Science, David Geffen School of Medicine at UCLA
Associate Director, UCLA Clinical and Translational Science Institute at The Lundquist Institute at Harbor-UCLA Medical Center

 

Please fill out the information below and one of our Study Coordinators will contact you:

OK for us to send text messages?

Thanks for submitting!

Location:

The Lundquist Institute
1124 West Carson Street
Torrance, CA 90502

Center of Men's health (4).png

We're inviting couples to take part in a clinical trial for a male contraceptive gel!

Men who wish to control their fertility currently have limited options. They have to rely on their female partner using contraceptives, use condoms, undergo vasectomy, or abstain.

This study is testing a gel as a possible new method for male family planning. It is a transparent gel applied daily to the skin of the shoulders. It aims to decrease a man’s sperm production in a reversible way without reducing sexual drive. The study also looks at the men’s compliance and the couple’s acceptance of this contraceptive method.

The study product is a combination hormone gel that contains Nestorone® and Testosterone. These hormones suppress the production of sperm to prevent the possibility of fathering a baby. Nestorone has been tested and shown to be safe and blocks the production of male hormones needed to make sperm. The testosterone in the gel works by replacing the testosterone that is normally produced by the body.

The study gel is being developed by The Population Council, a non-profit dedicated to reproductive health, in collaboration with the National Insitute of Health.

There will be no cost to you and your partner for the study medication, study doctor’s time or procedures related to this study. Compensation for your time is provided.

Study Length

 

The study will take approximately 2 years. Men will visit the clinic approximately 31 times and their female partner approximately 10 times.

The trial has 3 phases:

Who can participate:

We're looking for couples to participate. Men and their female partners are both active participants in the study and must both consent. See the main criteria for both men and women.

 

The male partner must:

  • Be healthy and between 18 and 50 years (inclusive) old.

  • Be sexually active with the female partner in a stable, mutually monogamous relationship for at least 1 year.

 

The female partner must:

  • Be healthy and between 18 and 34 years (inclusive) old.

  • Be sexually active with the male partner in a stable, mutually monogamous relationship for at least 1 year.

  • Have regular menstrual cycles of 21-35 days.

  • Have no known infertility.

 

Compensation

Male Partner: You may receive up to $2,985 for your participation.
Female Partner: You may receive up to $1,600 for your participation.

Resources

ClinicalTrials.gov: NCT03452111

Specific Trial Sites

United States, California

UC Davis Health

Sacramento, California, United States, 95817

Contact: UC Davis OBGYN    916-734-6886    hs-obgynresearch@ucdavis.edu   

Contact: UC Davis OBGYN    916-734-6846      

Principal Investigator: Mitchell Creinin         

 

The Lunquist Institute at Harbor-UCLA Medical Center

Torrance, California, United States, 90509

Contact: Xiaodan Han    310-341-9323    xhan@lundquist.org   

Contact: Elizabeth Ruiz    310-341-9323    eruiz@lundquist.org   

Principal Investigator: Christina Wang         

 

United States, Kansas

University of Kansas

Kansas City, Kansas, United States, 66160

United States, Oregon

Oregon Health & Science University

Portland, Oregon, United States, 97239

Contact: Morinne Osborne    503-494-3173    osbornmo@ohsu.edu   

Principal Investigator: Alison Edelman, MD         

 

United States, Pennsylvania

University of Pennsylvania Medical Center

Philadelphia, Pennsylvania, United States, 19104

Contact: Andrea Morley    215-615-4202    andrea.morley@pennmedicine.upenn.edu   

Contact: Nicole Clayton    215.615.4202    Nicole.clayton@pennmedicine.upenn.edu   

Principal Investigator: Kurt Barnhart, MD, MSCE         

 

United States, Virginia

Eastern Virginia Medical School-EVMS Obstetrics & Gynecology

Norfolk, Virginia, United States, 23507

Contact: Jamie Evans    757-446-7972    evansJL@EVMS.edu   

Principal Investigator: David Archer         

 

United States, Washington

University of Washington Medical Center & Health Sciences

Seattle, Washington, United States, 98195

Contact: Stephanie Page, MD, PhD    206-616-1818    page@uw.edu   

Contact: Kathy Winter    206-616-0484    klwinter@uw.edu   

Principal Investigator: Stephanie Page, MD, PhD         

 

Chile

Chilean Institute of Reproductive Medicine

Santiago, Chile, 8320000

Contact: Veronica Reyes    56-2-26335887    vreyes@icmer.org   

Contact: Fernanda Pinchetti    562 26328258    fpinchetti@icmer.org   

Principal Investigator: Gabriela Noe, MS         

 

 

Italy

University of Bologna, Italy

Bologna, Italy, 40138

Contact: Giulia Gava    +390512143716    gava.giulia@hotmail.it   

Contact: Silvia Cerpoini    +390512143716    silviacerpolini@gmail.com   

Principal Investigator: Cristina Meriggiola         

 

Kenya

Kenyatta National Hospital

Nairobi, Kenya, 00202

Contact: Sheila Eshiwani    254722799052    seshiwanin@gmail.com   

Contact: Anne Kaggiah       akaggiah@gmail.com   

Principal Investigator: John Kinuthia, MBChB, MPH         

 

Sweden

Karolinska Institutet

Stockholm, Sweden

Contact: Ulrika Fundin    46(8)517 721 28    ulrika.fundin@ki.se   

Contact: Anette Daberius    46(8)-517-721-28    anette.daberius@ki.se   

Principal Investigator: Kristina Gemzell-Danielsson, MD         

 

United Kingdom

University of Edinburgh

Edinburgh, United Kingdom, EH 16 4SA

Contact: Anne Saunderson    0131 242 2669    A.Saunderson@ed.ac.uk   

Contact: Norma Forson    0131 242 2669    norma.forson@ed.ac.uk   

Principal Investigator: Richard Anderson, MD, PhD         

 

University of Manchester, UK

Manchester, United Kingdom, M13 9WL

Contact: Verity Natale    0161 276 3296    Verity.Natale@cmft.nhs.uk   

Contact: Claudia Grant       claudia.grant@mft.nhs.uk   

Principal Investigator: Cheryl Fitzgerald, MD         

Supression

Men will start applying the gel once every day.

Efficacy

When the man's sperm count drops to an appropriate level to prevent pregnancy, the couple will begin to use the gel as their only form of contraception for one year. The man's sperm count will be checked regularly

Recovery

Men will stop using the gel and the study team will monitor recovery of sperm count.